Completed PHASE4 INTERVENTIONAL NCT00330655

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity

Sponsor: Forest Laboratories

Conditions Binge Eating Disorder

Interventions memantine

Updated 5 times since 2017 Last updated: Aug 10, 2007 Started: May 31, 2006 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Binge Eating Disorder, this trial is completed. The trial is conducted by Forest Laboratories and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
Mclean Hospital

Data source: Mclean Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Belmont, United States